This article first appeared on GuruFocus .
Release Date: May 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Talphera Inc ( NASDAQ:TLPH ) achieved a 50% enrollment milestone in the NEFRO study and has exceeded this level, indicating strong progress.
-
The company is on track to complete enrollment in the NEFRO CRRT study this year and plans to file a PMA for potential approval in 2027.
-
Nine out of twelve activated sites align with the new target site profile, with nephrologists as leads, contributing to over 90% of patient enrollment.
-
The study sites and principal investigators are highly engaged and supportive of the new CRRT anticoagulant.
-
Talphera Inc ( NASDAQ:TLPH ) has a cash balance of $21.1 million, which, combined with future financing tranches, is expected to support operations through potential NIAID PMA approval next year.
Negative Points
-
Cash operating expenses increased to $3.9 million in Q1 2026 from $2.9 million in Q1 2025, primarily due to higher NIAID development expenses.
-
The company is not planning additional enrollment updates until the study is completed, which may leave investors seeking more frequent updates.
-
Two new study sites are joining late and are not expected to significantly contribute to the study, potentially limiting their impact.
-
The study's completion and data announcement are dependent on the flow of qualifying patients, which could introduce timing uncertainties.
-
The company faces risks and uncertainties related to forward-looking statements, as highlighted in their SEC filings.
Q & A Highlights
Q: Are you planning to announce enrollment at any other milestone, like 75%, or will the next update be full enrollment? A: (Vince Angadi, CEO) We are not planning any additional enrollment updates until the study is completed. (Rafi Asadorian, CFO) We will announce the last patient out, and the top-line data should follow within a month after that.
Q: Is the second half of 2026 still the expected timeline for top-line data release? A: (Vince Angadi, CEO) Yes, we are maintaining our guidance for the second half of 2026 for the top-line data release, depending on the flow of qualifying patients.
Q: Can you disclose the new sites coming online and provide any feedback from site administrators? A: (Vince Angadi, CEO) The new sites are significant CRRT population centers but are joining late in the study. (Dr. Shakeel Aslam, CMO) Site administrators have been impressed with the ease of administering the intervention, noting stable test results and minimal variability.
Q: How are the sites managing anticoagulation, and what feedback have you received regarding the protocol? A: (Dr. Shakeel Aslam, CMO) Most sites do not use citrate or heparin as standard care but as rescue therapies. The protocol's simplicity and ease of use have been positively received, with nurses appreciating the reduced monitoring requirements.
Q: Can you elaborate on the stability of the dosing protocol and its impact on the study? A: (Dr. Shakeel Aslam, CMO) The study uses a predefined starting dose with quick adjustments based on activated clotting time. Nefamostat's metabolism is not organ-dependent, leading to stable responses and minimal dose adjustments.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
